Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gavreto
Pharma
Blueprint boosts Ayvakit peak sales estimate to $2B
Blueprint expects Ayvakit's 2024 revenue to come between $360 million and $390 million, which at the midpoint marks 84% year-over-year growth.
Angus Liu
Feb 15, 2024 7:00am
Lilly shows Roche how it's done in thyroid cancer niche
Aug 22, 2023 10:51am
Lilly pressures Blueprint further with positive NSCLC readout
Aug 4, 2023 10:40am
Roche pulls a Gavreto cancer indication, citing unfeasible trial
Jul 5, 2023 12:16pm
After splashing $1B, Roche returns Gavreto to Blueprint
Feb 23, 2023 11:29am
Roche, bracing for slowdown, names new pharma chief
Feb 2, 2023 11:25am
